JPH10279461A - Composition - Google Patents

Composition

Info

Publication number
JPH10279461A
JPH10279461A JP9099761A JP9976197A JPH10279461A JP H10279461 A JPH10279461 A JP H10279461A JP 9099761 A JP9099761 A JP 9099761A JP 9976197 A JP9976197 A JP 9976197A JP H10279461 A JPH10279461 A JP H10279461A
Authority
JP
Japan
Prior art keywords
extract
active oxygen
glycoside
lignan glycoside
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9099761A
Other languages
Japanese (ja)
Inventor
Kenichi Kuriyama
健一 栗山
Toshiko Yoshino
寿子 芳野
Haruko Hotta
晴子 堀田
Mikimasa Takisada
幹正 滝貞
Masami Senoo
正巳 妹尾
Hisami Kameyama
久美 亀山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nisshin Oil Mills Ltd
Original Assignee
Nisshin Oil Mills Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nisshin Oil Mills Ltd filed Critical Nisshin Oil Mills Ltd
Priority to JP9099761A priority Critical patent/JPH10279461A/en
Publication of JPH10279461A publication Critical patent/JPH10279461A/en
Pending legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain a composition, capable of improving effects essentially possessed by an active oxygen scavenger and effectively suppressing the production of peroxylipids and extremely useful for the beauty culture and medicine by using the active oxygen scavenger with a specific extract in combination. SOLUTION: This composition is obtained by formulating an active oxygen scavenger with a lignan glycoside in combination. A sesaminol glycoside represented by formula I [R1 and R2 are each glycosyl composed of one to four saccharides, which are one or more selected from glucose, galactose and fructose; (a) to (c) are each 0 or 1], especially a compound represented by formula II (Glc is the glycosyl) or formula III or IV is preferred. The amount of the formulated sesaminol glycoside is 0.001-5 wt.% in the case of using, e.g. the compound represented by formula 1 to IV. A superoxide dismutase, mannitol, hydroquinone, etc., are preferred as the active oxygen scavenger. The amount thereof formulated is 0.0001-5 wt.%.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、組成物に関し、更
に詳細には、リグナン配糖体と活性酸素除去剤を配合す
ることにより、皮膚内での活性酸素生成に起因する過酸
化脂質の生成や、肌の炎症、黒化、老化等を防止するこ
とのできる優れた老化防止効果、肌あれ改善効果等を有
する化粧品、外用医薬品等の組成物に関する。
[0001] The present invention relates to a composition, and more particularly, to the production of a lipid peroxide resulting from the production of active oxygen in the skin by combining a lignan glycoside with an active oxygen scavenger. The present invention also relates to compositions such as cosmetics and external medicines, which have excellent anti-aging effects and skin roughness improving effects capable of preventing skin inflammation, blackening, aging and the like.

【0002】[0002]

【従来の技術】従来より、乳液、クリーム、化粧水、パ
ック、洗浄料、ファンデーション、軟膏、分散液等の外
用剤には、これらに所定の薬効を付与することを目的と
して薬効成分が加えられている。近年では、皮膚老化の
原因の一つとして、生体に対する活性酸素の悪影響が挙
げられている。活性酸素には、一重項酸素、スーパーオ
キサイド、ヒドロキシラジカル、過酸化水素等がある
が、これらは過酸化脂質の生成や、核、タンパク質、酵
素にダメージを与えることが分かっており、これらが大
量に発生した場合には疾病や死を招くことがある。ま
た、量的には少なくとも、活性酸素に起因するダメージ
の蓄積により生体機能が低下して、いわゆる、老化現象
の一因になっている。このため、従来より様々な活性酸
素除去剤や抗酸化剤が開発されている。
2. Description of the Related Art Conventionally, medicinal ingredients have been added to external preparations such as emulsions, creams, lotions, packs, detergents, foundations, ointments, dispersions and the like for the purpose of imparting a prescribed medicinal effect to them. ing. In recent years, as one of the causes of skin aging, the adverse effect of active oxygen on the living body has been cited. Active oxygen includes singlet oxygen, superoxide, hydroxyl radical, hydrogen peroxide, etc., which are known to damage lipids, nuclei, proteins, and enzymes. If it occurs, it may cause illness or death. In addition, in terms of quantity, at least the accumulation of damage caused by active oxygen lowers the biological function, which is a cause of the so-called aging phenomenon. For this reason, various active oxygen removers and antioxidants have been conventionally developed.

【0003】[0003]

【発明が解決しようとする課題】従って、生体防御や老
化防止を目的として、高い効果を有する活性酸素除去剤
の開発が求められているが、生体系への適用を考慮した
場合、単にその効果のみならず、安全性の観点からも十
分満足できるものでなければならない。すなわち、優れ
た活性酸素除去及び/又は抗酸化効果を有し、なおかつ
生体系への適用に際しても好適な薬効成分の開発が望ま
れていた。
Therefore, there is a demand for the development of a highly effective active oxygen scavenger for the purpose of protecting the living body and preventing aging. In addition, it must be sufficiently satisfactory from the viewpoint of safety. That is, there has been a demand for the development of a medicinal component having an excellent active oxygen removal and / or antioxidant effect and suitable for application to biological systems.

【0004】[0004]

【課題を解決するための手段】本発明者らは、皮膚外用
剤の薬効成分の効果を向上させるべく鋭意検討を行った
結果、リグナン配糖体抽出物と活性酸素除去剤を組み合
わせれば、本来活性酸素除去剤の有する作用が十分発揮
されることを見出し、本発明を完成した。
Means for Solving the Problems The present inventors have conducted intensive studies to improve the effect of the medicinal component of the external preparation for skin, and as a result, when the lignan glycoside extract and the active oxygen scavenger are combined, The present inventors have found that the action of the active oxygen removing agent is sufficiently exhibited, and completed the present invention.

【0005】すなわち、本発明は、次の成分(A)及び
(B) (A)構造式(I)で示されるリグナン配糖体 (B)活性酸素消去剤
That is, the present invention relates to the following components (A) and (B): (A) a lignan glycoside represented by the structural formula (I): (B) an active oxygen scavenger

【化5】 を含有する組成物を提供するものであり、該リグナン配
糖体としては下記の構造式(II−a)、(II−b)
もしくは(II−c)で示されるセサミノール配糖体の
1種または2種以上を主成分として含有するものが好ま
しく、また好ましい実施態様としては前記リグナン配糖
体がゴマ種子やその加湿物もしくは発芽体、またはそれ
らの脱脂物の含水低級アルコール抽出物である。
Embedded image And lignan glycosides represented by the following structural formulas (II-a) and (II-b):
Or, those containing one or more of the sesaminol glycosides represented by (II-c) as a main component are preferable, and in a preferred embodiment, the lignan glycoside is a sesame seed or a humidified product thereof. It is a hydrated lower alcohol extract of germinated bodies or their defatted products.

【化6】 Embedded image

【化7】 Embedded image

【化8】 Embedded image

【0006】[0006]

【発明の実施の形態】本発明の(A)成分であるリグナ
ン配糖体を一般式で表現すれば、前記の構造式(I)で
示される。すなわち本発明に係るリグナン配糖体は、2
個のメチレンジオキシフェニル基を有するアグリコン部
分と、そのヒドロキシル基にグルコース、ガラクトース
またはフルクトースの糖残基が1〜4分子結合している
糖部分とから構成されるものである。
BEST MODE FOR CARRYING OUT THE INVENTION The lignan glycoside, which is the component (A) of the present invention, is represented by the above general formula (I). That is, the lignan glycoside according to the present invention comprises 2
The aglycone portion has a methylenedioxyphenyl group and a sugar portion in which one to four sugar residues of glucose, galactose or fructose are bonded to the hydroxyl group.

【0007】かかるリグナン配糖体は、好ましくは前記
構造式(I)において糖残基がジグルコシド残基および
/またはトリグルコシド残基であるグルコシドリグナン
であり、さらにより好ましくは前記の構造式(II−
a)、(II−b)もしくは(II−c)で示されるも
のの1種または2種以上、あるいはこれらを主成分とす
るものである。また、その調製法は特に限定されない
が、例えば、本発明者等によって開示された(特開平7
−145066号)方法がある。
[0007] The lignan glycoside is preferably glucoside lignan in which the sugar residue in the structural formula (I) is a diglucoside residue and / or a triglucoside residue, and still more preferably the structural formula (II) −
One, two or more of the compounds represented by a), (II-b) or (II-c), or those containing these as main components. Further, the method of preparing the same is not particularly limited.
No. 145066).

【0008】本発明の組成物におけるリグナン配糖体類
の含有量は、リグナン配糖体の各成分の含有率の相違に
より一律に規定しがたいが、例えば特開平7−1450
66号に開示された方法により調製された含水低級アル
コール抽出物のときは、0.05〜20重量%(以下単
に「%」で示す)、好ましくは0.1〜10%であり、
粗リグナン配糖体を配合するときは0.01〜10%、
好ましくは0.05〜5%であり、また、高純度精製物
(前記構造式(I)、(II−a)、(II−b)また
は(II−c)で示されるリグナン配糖体のうち少なく
とも1種以上を合計量として約60%以上含む。)を用
いるときは0.001〜5%、好ましくは0.01〜1
%である。
[0008] The content of lignan glycosides in the composition of the present invention cannot be uniformly defined by the difference in the content of each component of the lignan glycoside.
In the case of the aqueous lower alcohol extract prepared by the method disclosed in No. 66, the content is 0.05 to 20% by weight (hereinafter simply referred to as “%”), preferably 0.1 to 10%,
0.01 to 10% when blending crude lignan glycoside,
It is preferably 0.05 to 5%, and a highly purified product (of the lignan glycoside represented by the structural formula (I), (II-a), (II-b) or (II-c)) When at least one of them is contained in a total amount of about 60% or more), 0.001 to 5%, preferably 0.01 to 1%.
%.

【0009】一方、本発明の(B)成分である活性酸素
消去剤は、以下に示すものが挙げられる。
On the other hand, the active oxygen scavenger as the component (B) of the present invention includes the following.

【0010】スーパーオキシドディスムターゼ(以下S
ODと略す)、マンニトール、ベーターカロチン等のカ
ロテノイド類、ハイドロキノン、ビリルビン、トリプト
ファン、ヒスチジン、クエルセチン、クエルシトリン、
カテキン及びその誘導体、没食子酸及びその誘導体、オ
ウゴン抽出物及びイチョウ抽出物等のフラボノイドを成
分中に含む植物抽出物、ユキノシタ抽出物、ゴカヒ抽出
物、ヤシャジツ抽出物及びジコッピ抽出物等が挙げら
れ、これらの1種又は2種以上を組み合わせて用いても
良い。
[0010] Superoxide dismutase (hereinafter referred to as S
OD), mannitol, carotenoids such as beta-carotene, hydroquinone, bilirubin, tryptophan, histidine, quercetin, quercitrin,
Catechin and its derivatives, gallic acid and its derivatives, plant extracts containing flavonoids such as gougon extract and ginkgo extract in its components, saxifrage extract, gokahi extract, yasajitsu extract and dicopi extract, and the like, One or more of these may be used in combination.

【0011】これら活性酸素消去剤のうち、特に好まし
いものとしては、SOD、マンニトール、ベーターカロ
チン等のカロテノイド類、ハイドロキノン、カテキン及
びその誘導体、オウゴン抽出物、イチョウ抽出物、ユキ
ノシタ抽出物、ゴカヒ抽出物、ヤシャジツ抽出物及びジ
コッピ抽出物等が挙げられる。これらの各成分は、その
起源について特に制約はなく、動物由来、微生物由来、
合成品のいずれであってもよい。また、その抽出方法、
精製処理方法等、製法についても特に制約されない。
Among these active oxygen scavengers, particularly preferred are carotenoids such as SOD, mannitol, beta-carotene, hydroquinone, catechin and derivatives thereof, pentagon extract, ginkgo extract, saxifrage extract, and kokahi extract. , Jasazi extract and dickopi extract. Each of these components is not particularly limited in its origin, and is derived from animals, microorganisms,
Any of synthetic products may be used. Also, the extraction method,
The production method such as the purification treatment method is not particularly limited.

【0012】本発明の組成物における上記(B)成分の
配合量は、特に限定されないが、活性酸素除去剤として
好ましくは、0.0001〜5%、より好ましくは、
0.001〜3%である。この範囲であれば優れた皮膚
老化防止効果、肌あれ改善効果が得られる。すなわち、
皮膚内での活性酸素生成に起因する過酸化脂質の生成
や、肌の炎症、黒化、老化等の防止に有効である。な
お、これらの活性酸素除去剤は1種又は2種以上を組み
合わせて用いることができる。
The amount of the component (B) in the composition of the present invention is not particularly limited, but is preferably 0.0001 to 5% as an active oxygen remover, more preferably
0.001 to 3%. Within this range, excellent effects of preventing skin aging and improving skin roughness can be obtained. That is,
It is effective in preventing the formation of lipid peroxide due to the generation of active oxygen in the skin and the prevention of skin inflammation, blackening, aging and the like. These active oxygen removers can be used alone or in combination of two or more.

【0013】本発明の組成物は、常法に従い必須成分で
ある(A)成分と(B)成分とを通常の皮膚外用剤とし
て知られる種々の形態の基剤に配合して調製することが
できる。
The composition of the present invention can be prepared by blending the essential components (A) and (B) with various types of bases known as ordinary skin external preparations according to a conventional method. it can.

【0014】外用剤の形態としては、特に限定されず、
例えば、乳液、クリーム、化粧水、パック、洗浄料等の
スキンケア化粧料、口紅、ファンデーション等のメーキ
ャップ化粧料、頭皮・毛髪用化粧料や、軟膏剤、分散
液、クリーム剤、外用液剤などの医薬品等とすることが
できる。
The form of the external preparation is not particularly limited.
For example, skin care cosmetics such as milky lotions, creams, lotions, packs, cleaning agents, makeup cosmetics such as lipsticks and foundations, cosmetics for the scalp and hair, and pharmaceuticals such as ointments, dispersions, creams, and external solutions And so on.

【0015】本発明の組成物には、上記した必須成分の
他に通常の外用剤に配合される成分、例えば、油剤、粉
体、界面活性剤、精製水、低級アルコール、高分子化合
物、ゲル化剤、紫外線吸収剤、紫外線散乱剤、酸化防止
剤、色素、防腐剤、香料、美容成分等を本発明の効果を
損なわない範囲で適宜選択して用いることができる。
In the composition of the present invention, in addition to the above-mentioned essential components, components to be blended with ordinary external preparations, for example, oils, powders, surfactants, purified water, lower alcohols, polymer compounds, gels An agent, an ultraviolet absorber, an ultraviolet scattering agent, an antioxidant, a dye, a preservative, a fragrance, a cosmetic ingredient, and the like can be appropriately selected and used within a range not to impair the effects of the present invention.

【0016】[0016]

【実施例】次に参考例、試験例及び実施例を挙げて本発
明を更に詳細に説明するが、本発明はこれらになんら制
約されるものではない。
EXAMPLES Next, the present invention will be described in more detail with reference to Reference Examples, Test Examples and Examples, but the present invention is not limited thereto.

【0017】参考例1 含水メタノール抽出物の製造 予め滅菌した石英砂を300cm2 のステンレス製のバ
ットに敷き、その上に中国産ゴマ種子10gを撒き、蒸
留水を十分に噴霧しながら、40℃の恒温槽中で2日間
培養し、発芽させた。発芽率は89%以上であった。発
芽状態が同程度の一定量の発芽物を100mlの含水メ
タノール(80%(v/v))とともにブレンダーで粉
砕した。残渣を濾過し、濾液を濃縮乾固してメタノール
抽出物を得た。ついで、該抽出物をn−ヘキサンで抽出
洗浄して脂溶性物質を除き、含水メタノール抽出物を得
た。この含水メタノール抽出物を100ml含水メタノ
ール(80%(v/v))に再溶解し、高速液体クロマ
トグラフィー(HPLC)に供して組成を分析した。
Reference Example 1 Production of aqueous methanol extract Pre-sterilized quartz sand was spread on a stainless steel vat of 300 cm 2 , and 10 g of Chinese sesame seeds were sprinkled thereon. And germinated for 2 days in a constant temperature bath. The germination rate was 89% or more. A certain amount of germinated material having a similar germination state was ground with a blender together with 100 ml of hydrated methanol (80% (v / v)). The residue was filtered, and the filtrate was concentrated to dryness to obtain a methanol extract. Then, the extract was washed by extraction with n-hexane to remove fat-soluble substances, thereby obtaining a water-containing methanol extract. The aqueous methanol extract was redissolved in 100 ml of aqueous methanol (80% (v / v)) and subjected to high performance liquid chromatography (HPLC) to analyze the composition.

【0018】HPLC条件は、ポンプ(CCPM、東ソ
ー社製)にカラム(Soken Pak ODS−W5
μ、10mmΦ×250mm)、紫外線吸収検出器(U
V−8000、東ソー社製)を接続し、溶出は、水:メ
タノールが90:10(v:v)から開始して、60分
後に同10:90(v:v)となる直線グラジェントを
用い、流速を1ml/min、検出波長は280nmと
した。
The HPLC conditions were as follows: a pump (CCPM, manufactured by Tosoh Corporation) was used and a column (Soken Pak ODS-W5) was used.
μ, 10 mmΦ × 250 mm), UV absorption detector (U
V-8000, manufactured by Tosoh Corporation), elution was performed using a linear gradient of water: methanol starting at 90:10 (v: v) and 60:60 minutes later at 10:90 (v: v). The flow rate was 1 ml / min, and the detection wavelength was 280 nm.

【0019】HPLC分析の結果、セサミンを外標準と
して含水メタノール抽出物中のリグナン配糖体の組成及
び含量を求めたところ、セサミノールトリグリコシド
(構造式(II−a))、セサミノールジグリコシド
(構造式(II−b))及びセサミノールモノグリコシ
ド(構造式(II−c))の3種を含み、これらは含水
メタノール抽出物中に80mg存在し、その組成はセサ
ミノールトリグリコシドが40%、セサミノールジグリ
コシドが50%、セサミノールモノグリコシドが10%
であった。
As a result of HPLC analysis, the composition and content of lignan glycosides in the aqueous methanol extract were determined using sesamin as an external standard, and sesaminol triglycoside (structural formula (II-a)), sesaminol diglycoside (Structural Formula (II-b)) and Sesaminol monoglycoside (Structural Formula (II-c)), which are present in a hydrous methanol extract in an amount of 80 mg. %, Sesaminol diglycoside 50%, sesaminol monoglycoside 10%
Met.

【0020】なお、各リグナン配糖体成分の化学的構造
は、前記と同条件の分取HPLCで単一成分まで高純度
化した各精製物を用い、次の方法により確認した。即
ち、各精製物に1N塩酸を加え、100℃で30分間加
水分解せしめた後、酢酸エチルで抽出し、酢酸エチル層
及び水層に分けた。酢酸エチル層は40℃以下で濃縮乾
固、TMS−PZ(東京化成工業社製)でトリメチルシ
リル化処理し、ガスクロマトグラフィー(GLC)に供
してリグナンを定量分析した(外標準:セサミン)。
The chemical structure of each lignan glycoside component was confirmed by the following method using each purified product purified to a single component by preparative HPLC under the same conditions as described above. That is, 1N hydrochloric acid was added to each purified product, hydrolyzed at 100 ° C. for 30 minutes, extracted with ethyl acetate, and separated into an ethyl acetate layer and an aqueous layer. The ethyl acetate layer was concentrated to dryness at 40 ° C. or lower, subjected to trimethylsilylation treatment with TMS-PZ (manufactured by Tokyo Chemical Industry Co., Ltd.), and subjected to gas chromatography (GLC) to quantitatively analyze lignan (external standard: sesamin).

【0021】このGLC条件は次のとおり。GLC装
置:ヒューレットパッカード社製5890、カラム:D
B−17HT(15m×0.319mm、film t
hickness:0.15μm、J&W SCIEN
TIFIC社製)、注入法:スプリット法(スプリット
比1/10)、カラム温度:270℃、キャリアガス:
ヘリウム。
The GLC conditions are as follows. GLC apparatus: Hewlett-Packard 5890, column: D
B-17HT (15mx0.319mm, film t
kickness: 0.15 μm, J & W SCIEN
TIFIC), injection method: split method (split ratio 1/10), column temperature: 270 ° C., carrier gas:
helium.

【0022】また、水層をHPLC用前処理フィルター
(孔径:0.2μm、マイショリディスクW−13−
2、東ソー社製)で濾過し、濾液にアセトン5mlを加
えて減圧下で濃縮乾固後、TMS−PZ(前出と同じ)
でトリメチルシリル化処理し、これをGLCに供して糖
を定量分析した(外標準:グルコース、ガラクトース、
フルクトース)。
The aqueous layer was subjected to a pretreatment filter for HPLC (pore size: 0.2 μm, Meishoridisk W-13).
2, Tosoh Corporation), add 5 ml of acetone to the filtrate, concentrate under reduced pressure to dryness, and then TMS-PZ (same as above)
And subjected to GLC for quantitative analysis of sugars (external standard: glucose, galactose,
Fructose).

【0023】このGLC条件は、カラム:DB−170
1(15m×0.25mm、film thickne
ss:1.0μm、J&W SCIENTIFIC社
製)、注入法:スプリット法(スプリット比1/5
0)、カラム温度:180℃とする以外は前記リグナン
分析の場合と同じである。
The GLC conditions are as follows: Column: DB-170
1 (15m x 0.25mm, film thickne
ss: 1.0 μm, manufactured by J & W SCIENTIFIC) Injection method: split method (split ratio 1/5)
0), except that the column temperature was set to 180 ° C.

【0024】参考例2 粗リグナン配糖体の製造 参考例1と同様の方法で得た含水メタノール抽出物を水
100mlに分散させ、同容量のn−ヘキサンを加え激
しく振盪した。この抽出操作を3回繰り返し、脂溶性物
質を除いた。n−ヘキサン層を完全に除いた残液に予め
水で飽和したn−ブタノールを同容量加え、激しく振盪
した。この抽出操作を2回繰り返し、水溶性物質を除い
た。n−ブタノール層を同容量の水で2回水洗した後、
減圧下で濃縮乾固して粗リグナン配糖体を得た。
Reference Example 2 Production of Crude Lignan Glycoside A hydrous methanol extract obtained in the same manner as in Reference Example 1 was dispersed in 100 ml of water, and the same volume of n-hexane was added and shaken vigorously. This extraction operation was repeated three times to remove fat-soluble substances. To the residual solution from which the n-hexane layer was completely removed, the same volume of n-butanol which had been saturated with water in advance was added, and the mixture was vigorously shaken. This extraction operation was repeated twice to remove water-soluble substances. After washing the n-butanol layer twice with the same volume of water,
It was concentrated to dryness under reduced pressure to obtain a crude lignan glycoside.

【0025】参考例1に記載の方法でHPLC分析した
ところ、粗リグナン配糖体中のリグナン配糖体はセサミ
ノールトリグリコシド、セサミノールジグリコシド及び
セサミノールモノグリコシドを含み、これらは粗リグナ
ン配糖体中に70mg存在し、その組成はセサミノール
トリグリコシドが45%、セサミノールジグリコシドが
48%、セサミノールモノグリコシドが7%であった。
According to HPLC analysis by the method described in Reference Example 1, the lignan glycosides in the crude lignan glycoside include sesaminol triglycoside, sesaminol diglycoside and sesaminol monoglycoside, which are crude lignan glycosides. The saccharide contained 70 mg, and its composition was 45% sesaminol triglycoside, 48% sesaminol diglycoside, and 7% sesaminol monoglycoside.

【0026】参考例3 高純度リグナン配糖体精製物の
製造 参考例2に記載の方法で得られた粗リグナン配糖体を、
ODSを担体とする分配クロマトグラフィーに供した。
YMC−GEL ODS−A(山村化学(株)製)60
gを直径3cm、長さ50cmのガラス製カラムに充填
して水を流して平衡化した。これに前記粗リグナン配糖
体1gをカラムの上部に負荷した。水から順次メタノー
ル濃度を増加させる段階溶出法によって、分画成分を溶
出させた。30〜60%(v/v)メタノールで溶出す
る画分を集め、減圧濃縮したところ、約100mgのカ
ラム分画物が得られた。
Reference Example 3 Production of Highly Purified Lignan Glycoside The crude lignan glycoside obtained by the method described in Reference Example 2 was
The resultant was subjected to partition chromatography using ODS as a carrier.
YMC-GEL ODS-A (Yamamura Chemical Co., Ltd.) 60
g was packed in a glass column having a diameter of 3 cm and a length of 50 cm, and equilibrated by flowing water. To this, 1 g of the crude lignan glycoside was loaded on the top of the column. The fraction components were eluted by a step elution method in which the methanol concentration was sequentially increased from water. Fractions eluted with 30-60% (v / v) methanol were collected and concentrated under reduced pressure to obtain about 100 mg of a column fraction.

【0027】これを分取HPLCに繰り返し供して、各
リグナン配糖体成分が単一となるまで精製を行なった。
その結果、セサミノールトリグリコシド、セサミノール
ジグリコシド及びセサミノールモノグリコシドの各リグ
ナン配糖体精製物が各5〜10mg得られた。これらの
全リグナン配糖体成分の含有率は、発芽乾燥物当たり
2.0%(wt/wt)、含水メタノール抽出物当たり
4.5%(wt/wt)であった。
This was repeatedly subjected to preparative HPLC, and purification was performed until each lignan glycoside component became single.
As a result, 5 to 10 mg of each purified lignan glycoside of sesaminol triglycoside, sesaminol diglycoside and sesaminol monoglycoside was obtained. The content of all these lignan glycoside components was 2.0% (wt / wt) per dried germination product and 4.5% (wt / wt) per hydrated methanol extract.

【0028】参考例4 オウゴン抽出物の製造 オウゴン(コガネバナの根)10gを細切し、無水エタ
ノール100mlを加え、時々撹拌しながら室温で5日
間抽出し、濾過してオウゴン抽出物を得た。
REFERENCE EXAMPLE 4 Production of Orgon Extract A 10 g of Orgon (Scarabae root) was cut into small pieces, 100 ml of absolute ethanol was added, the mixture was extracted at room temperature for 5 days with occasional stirring, and filtered to obtain an Orgon extract.

【0029】参考例5 ゴカヒ抽出物の製造 ゴカヒの全草10gを細切し、含水濃度50%(v/
v)エタノール100mlを添加し、時々撹拌しながら
室温で3日間抽出し、濾過してゴカヒ抽出物を得た。
Reference Example 5 Production of Gokahi Extract 10 g of whole Gokahi plant was cut into small pieces and the water content was 50% (v /
v) 100 ml of ethanol was added, and the mixture was extracted at room temperature for 3 days with occasional stirring, and filtered to obtain a mosquito extract.

【0030】参考例6 ユキノシタ抽出物の製造 ユキノシタの全草25gを細切し、30%(v/v)
1,3−ブチレングリコール300mlを加え、時々撹
拌しながら室温で3日間抽出し、濾過してユキノシタ抽
出物を得た。
Reference Example 6 Production of Saxifraga extract 25 g of Saxifraga whole plant was finely cut and 30% (v / v)
300 ml of 1,3-butylene glycol was added, extracted at room temperature for 3 days with occasional stirring, and filtered to obtain a saxifrage extract.

【0031】試験例1 スーパーオキサイド除去活性測
定試験 リグナン配糖体と表1記載の活性酸素除去剤を、それぞ
れ単独または混合して試料とし、水で希釈後、下記測定
方法により、スーパーオキサイド除去活性を測定した。
Test Example 1 Test for measuring superoxide removal activity The lignan glycoside and the active oxygen remover listed in Table 1 were used alone or in combination as a sample, diluted with water, and then subjected to the following measurement method to determine the superoxide removal activity. Was measured.

【0032】(測定方法)0.05M 炭酸ナトリウム
緩衝液(pH10.2)2.4mlに基質溶液[3.0
mM キサンチン(0.05M 炭酸ナトリウム緩衝液
に溶解)]0.1ml,3.0mM EDTA 0.1
ml、0.15%(w/v)ウシ血清アルブミン 0.
1ml、0.75mM ニトロブルーテトラゾリウム
0.1ml及び各被験試料0.1mlを混合し、25℃
で10分間放置した。次いで、酵素溶液[キサンチンオ
キシダーゼ溶液(精製水にて約0.04units/m
lに希釈)]0.1mlを加えて反応を開始し、25℃
で20分間インキュベートした後、6mM CaCl2
0.1mlを加えて反応を停止する。次いで560nm
における吸光度(A)を測定する。
(Measurement method) A substrate solution [3.0] was added to 2.4 ml of a 0.05 M sodium carbonate buffer (pH 10.2).
mM xanthine (dissolved in 0.05 M sodium carbonate buffer)] 0.1 ml, 3.0 mM EDTA 0.1
ml, 0.15% (w / v) bovine serum albumin
1 ml, 0.75 mM nitro blue tetrazolium
0.1 ml and 0.1 ml of each test sample were mixed at 25 ° C.
For 10 minutes. Then, an enzyme solution [xanthine oxidase solution (about 0.04 units / m in purified water)
The reaction was started by adding 0.1 ml and the reaction was started at 25 ° C.
After incubation for 20 minutes in 6 mM CaCl 2
The reaction is stopped by adding 0.1 ml. Then 560 nm
The absorbance (A) at is measured.

【0033】対照には被験試料のかわりに精製水を加え
た試料の吸光度(B)、また各試料のブランクには、6
mM CaCl20.1mlを加えて反応停止後に、キ
サンチンオキシダーゼ0.1mlを添加した試料の吸光
度(C)を測定し、次式より、スーパーオキサイド除去
率を算出した。その結果を表1に示す。
As a control, the absorbance (B) of a sample to which purified water was added instead of the test sample, and 6 blanks for each sample.
After stopping the reaction by adding 20.1 ml of mM CaCl, the absorbance (C) of the sample to which 0.1 ml of xanthine oxidase was added was measured, and the superoxide removal rate was calculated from the following equation. Table 1 shows the results.

【0034】[0034]

【数1】 A:試料の酵素反応による吸光度 B:対照の酵素反応による吸光度 C:試料の無酵素反応による吸光度(Equation 1) A: Absorbance of sample by enzyme reaction B: Absorbance of control by enzyme reaction C: Absorbance of sample by non-enzyme reaction

【0035】[0035]

【表1】 *1:参考例3で製造したもの *2:シグマ社製;ウシ赤血球より得たもの(3.570units/mg ) *3:参考例4で製造したもの[Table 1] * 1: Manufactured in Reference Example 3 * 2: Sigma; obtained from bovine erythrocytes (3.570 units / mg) * 3: Manufactured in Reference Example 4

【0036】表1の結果より明らかなように、リグナン
配糖体は単独でもSOD様活性を有していたが、SOD
及びオウゴン抽出物と併用することにより、相乗的な作
用を発揮し、活性酸素除去に極めて有効であることが示
された。
As is clear from the results shown in Table 1, the lignan glycoside alone had SOD-like activity,
In addition, the use of the extract in combination with the pentagon extract showed a synergistic effect and was extremely effective in removing active oxygen.

【0037】実施例1 クリーム:表2に示す組成及び
下記製法でクリームを調製し、その美肌効果及び皮膚老
化防止効果を調べた。この結果も併せて表2に示す。
Example 1 Cream: A cream was prepared by the composition shown in Table 2 and by the following production method, and its beautiful skin effect and skin aging prevention effect were examined. The results are also shown in Table 2.

【0038】[0038]

【表2】 *1:参考例1で製造したもの *2:参考例5で製造したもの *3:和光純薬社製[Table 2] * 1: Manufactured in Reference Example 1 * 2: Manufactured in Reference Example 5 * 3: Wako Pure Chemical Industries

【0039】(製法) A.成分(1)〜(7)、(11)及び(12)を混合
し、加熱して70℃に保つ。 B.成分(8)及び(13)を混合し、加熱して70℃
に保つ。 C.AにBを加え、混合した後、冷却して(9)及び
(10)を加えて均一に混合してクリームを得た。
(Production method) Components (1)-(7), (11) and (12) are mixed and heated to 70 ° C. B. Mix components (8) and (13) and heat to 70 ° C
To keep. C. After B was added to A and mixed, the mixture was cooled, (9) and (10) were added, and the mixture was uniformly mixed to obtain a cream.

【0040】(試験方法)被験クリーム1品につき25
〜55才の女性15名をパネルとし、毎日朝と夜の2
回、12週間にわたって洗顔後に被験クリームの適量を
顔面に塗布した。塗布による美肌及び皮膚老化防止効果
を以下の基準によって評価した。
(Test method) 25 per test cream
A panel consisting of 15 women aged 55 to 55
After washing the face for 12 weeks, an appropriate amount of the test cream was applied to the face. The skin and skin aging prevention effects of the application were evaluated according to the following criteria.

【0041】(評価基準) 美肌効果: <評価> <内 容> 有 効 肌のくすみが目立たなくなった。 やや有効 肌のくすみがあまり目立たなくなった。 無 効 使用前と変化なし。(Evaluation criteria) Beautifying effect: <Evaluation> <Contents> Effective The dullness of the skin became less noticeable. Slightly effective The dullness of the skin became less noticeable. Ineffective No change from before use.

【0042】皮膚老化防止効果: <評価> <内 容> 有 効 肌のはり、つやが改善された。 やや有効 肌のはり、つやがやや改善された。 無 効 使用前と変化なし。Anti-aging effect of skin: <Evaluation> <Contents> Effective Skin laxity and gloss were improved. Slightly effective Skin glue, gloss slightly improved. Ineffective No change from before use.

【0043】表2の結果に示す如く、本発明品1及び2
に代表されるリグナン配糖体抽出物と活性酸素除去剤を
配合したクリームを皮膚に適用することにより、肌の
「くすみ」等の発生の防止、美しい肌とするとともに、
肌のはり、つやが改善され、皮膚の老化を防止すること
が明らかとなった。
As shown in Table 2, the products of the present invention 1 and 2
By applying to the skin a cream that contains a lignan glycoside extract and an active oxygen remover represented by, the prevention of the occurrence of "dullness", etc., and beautiful skin,
It has been revealed that skin abrasion and gloss are improved and that skin aging is prevented.

【0044】実施例2 化粧水:次に示す処方及び下記
製法で化粧水を調製した。 (処方) (%) (1)グリセリン 6.0 (2)1,3−ブチレングリコール 5.5 (3)ポリオキシエチレン(20E.O.)ソルビタン 1.5 モノラウレート (4)エタノール 9.0 (5)含水メタノール抽出物*1 10.0 (6)マンニトール*2 0.5 (7)防腐剤 適量 (8)香料 適量 (9)精製水 残量 *1 参考例1で製造したもの *2 関東化学社製
Example 2 Lotion: A lotion was prepared according to the following formulation and the following method. (Prescription) (%) (1) Glycerin 6.0 (2) 1,3-butylene glycol 5.5 (3) Polyoxyethylene (20EO) sorbitan 1.5 monolaurate (4) Ethanol 9. 0 (5) Hydrous methanol extract * 1 10.0 (6) Mannitol * 2 0.5 (7) Preservative appropriate amount (8) Perfume appropriate amount (9) Purified water balance * 1 Produced in Reference Example 1 * 2 Kanto Chemical Co., Ltd.

【0045】(製法) A.成分(3)、(4)、(7)及び(8)を混合溶解
する。 B.成分(1)、(2)、(5)、(6)及び(9)を
混合溶解する。 C.AとBを混合して均一にし、化粧水を得た。
(Production method) Components (3), (4), (7) and (8) are mixed and dissolved. B. Components (1), (2), (5), (6) and (9) are mixed and dissolved. C. A and B were mixed and made uniform to obtain a lotion.

【0046】実施例3 乳液:次に示す処方及び下記製
法で乳液を調製した。 (処方) (%) (1)ポリオキシエチレン(10E.O.)ソルビタン 1.0 モノステアレート (2)ポリオキシエチレン(60E.O.)ソルビタン 0.5 テトラオレエート (3)グリセリルモノステアレート 1.0 (4)ステアリン酸 0.5 (5)ベヘニルアルコール 0.5 (6)スクワラン 8.0 (7)粗リグナン配糖体*1 3.0 (8)エルゴカルシフェロール*2 0.02 (9)オウゴン抽出物*3 1.0 (10)防腐剤 0.1 (11)カルボキシビニルポリマー 0.1 (12)水酸化ナトリウム 0.05 (13)エタノール 5.0 (14)精製水 残量 (15)香料 適量 *1 参考例2で製造したもの *2 シグマ社製 *3 参考例4で製造したもの
Example 3 Emulsion: An emulsion was prepared according to the following formulation and the following production method. (Formulation) (%) (1) Polyoxyethylene (10EO) sorbitan 1.0 monostearate (2) Polyoxyethylene (60EO) sorbitan 0.5 tetraoleate (3) Glyceryl monostea Rate 1.0 (4) Stearic acid 0.5 (5) Behenyl alcohol 0.5 (6) Squalane 8.0 (7) Crude lignan glycoside * 1 3.0 (8) Ergocalciferol * 2 0.02 (9) Ogre extract * 3 1.0 (10) Preservative 0.1 (11) Carboxyvinyl polymer 0.1 (12) Sodium hydroxide 0.05 (13) Ethanol 5.0 (14) Purified water residue Amount (15) Appropriate amount of fragrance * 1 Manufactured in Reference Example 2 * 2 Sigma * 3 Manufactured in Reference Example 4

【0047】(製法) A.成分(9)〜(14)を加熱混合し、70℃に保
つ。 B.成分(1)〜(6)を加熱混合し、70℃に保つ。 C.BにAを加えて混合し、均一に乳化する。 D.Cを冷却後(7)、(8)及び(15)を加え、均
一に混合して乳液を得た。
(Production method) The components (9) to (14) are mixed by heating and kept at 70 ° C. B. The components (1) to (6) are mixed by heating and kept at 70 ° C. C. Add A to B, mix and emulsify uniformly. D. After cooling C, (7), (8) and (15) were added and mixed uniformly to obtain an emulsion.

【0048】実施例4 軟膏:次に示す処方及び下記製
法で軟膏を調製した。 (処方) (%) (1)ステアリン酸 18.0 (2)セタノール 4.0 (3)トリエタノールアミン 2.0 (4)グリセリン 5.0 (5)高純度リグナン配糖体精製物*1 2.0 (6)カテキン*2 0.5 (7)精製水 残量 *1 参考例3で製造したもの *2 シグマ社製
Example 4 Ointment: An ointment was prepared according to the following formulation and the following production method. (Prescription) (%) (1) Stearic acid 18.0 (2) Cetanol 4.0 (3) Triethanolamine 2.0 (4) Glycerin 5.0 (5) High-purity purified lignan glycoside * 1 2.0 (6) Catechin * 2 0.5 (7) Remaining purified water * 1 Produced in Reference Example 3 * 2 Sigma

【0049】(製法) A.成分(3)、(4)及び(7)の一部を加熱混合
し、75℃に保つ。 B.成分(1)及び(2)を加熱混合し、75℃に保
つ。 C.AをBに徐々に加える。 D.Cを冷却しながら(7)の残部で溶解した(5)、
(6)を加え、軟膏を得た。
(Production method) A part of components (3), (4) and (7) are mixed by heating and kept at 75 ° C. B. Heat mix components (1) and (2) and maintain at 75 ° C. C. Add A slowly to B. D. C was dissolved in the remainder of (7) while cooling (5),
(6) was added to obtain an ointment.

【0050】実施例2の化粧水、実施例3の乳液及び実
施例4の軟膏はいずれも経時安定性に優れ、皮膚に適用
することにより、肌のはり、つやが改善され、肌のくす
みや皮膚の老化を防止するものであった。
The lotion of Example 2, the lotion of Example 3, and the ointment of Example 4 are all excellent in stability over time, and when applied to the skin, the skin will be improved in terms of radiance and luster, and dullness of the skin will be improved. It prevented skin aging.

【0051】実施例5 洗浄料:次に示す処方及び下記
製法で洗浄料を調製した。 (処方) (%) (1)ステアリン酸 10.0 (2)パルミチン酸 8.0 (3)ミリスチン酸 12.0 (4)ラウリン酸 4.0 (5)オレイルアルコール 1.5 (6)精製ラノリン 1.0 (7)香料 適量 (8)防腐剤 0.1 (9)水酸化カリウム 6.0 (10)高純度リグナン配糖体精製物*1 0.5 (11)オウゴン抽出物*2 0.5 (12)精製水 残量 *1 参考例3で製造したもの *2 参考例4で製造したもの
Example 5 Cleaning agent: A cleaning agent was prepared according to the following formulation and the following production method. (Prescription) (%) (1) Stearic acid 10.0 (2) Palmitic acid 8.0 (3) Myristic acid 12.0 (4) Lauric acid 4.0 (5) Oleyl alcohol 1.5 (6) Purification Lanolin 1.0 (7) Appropriate amount of fragrance (8) Preservative 0.1 (9) Potassium hydroxide 6.0 (10) High-purity purified lignan glycoside * 1 0.5 (11) Japanese gogon extract * 2 0.5 (12) Remaining purified water * 1 Manufactured in Reference Example 3 * 2 Manufactured in Reference Example 4

【0052】(製法) A.成分(9)及び(12)を加熱混合し、70℃に保
つ。 B.成分(1)〜(6)及び(8)を加熱混合し、70
℃に保つ。 C.BにAを加えてしばらく70℃に保ち、けん化反応
が終了後、50℃まで冷却し、成分(7)、(10)及
び(11)を加え、冷却して洗浄料を得た。
(Production method) A. Heat and mix components (9) and (12) and maintain at 70 ° C. B. Components (1) to (6) and (8) were mixed by heating.
Keep at ° C. C. A was added to B and maintained at 70 ° C. for a while. After the saponification reaction was completed, the mixture was cooled to 50 ° C., and components (7), (10) and (11) were added, and the mixture was cooled to obtain a cleaning agent.

【0053】実施例5の洗浄剤は、経時安定性に優れ、
皮膚に適用することによって、洗いあがりがしっとりと
して保湿性に優れ、肌のキメを整え、はり、つやを与え
るものであった。
The cleaning agent of Example 5 has excellent stability over time,
By applying to the skin, the skin was moisturized and excellent in moisturizing properties, and the texture of the skin was adjusted, and the skin was polished and glossed.

【0054】実施例6 パック:次に示す処方及び下記
製法でパックを調製した。 (処方) (%) (1)ポリビニルアルコール 20.0 (2)エタノール 20.0 (3)グリセリン 5.0 (4)カオリン 6.0 (5)含水メタノール抽出物*1 1.0 (6)ユキノシタ抽出物*2 0.2 (7)防腐剤 適量 (8)香料 0.05 (9)精製水 残量 *1 参考例1で製造したもの *2 参考例6で製造したもの
Example 6 Pack: A pack was prepared according to the following formulation and the following production method. (Prescription) (%) (1) Polyvinyl alcohol 20.0 (2) Ethanol 20.0 (3) Glycerin 5.0 (4) Kaolin 6.0 (5) Hydrous methanol extract * 1 1.0 (6) Saxifraga extract * 2 0.2 (7) Preservative appropriate amount (8) Perfume 0.05 (9) Purified water remaining * 1 Manufactured in Reference Example 1 * 2 Manufactured in Reference Example 6

【0055】(製法) A.成分(1)、(3)〜(6)及び(9)を混合し、
70℃に加熱し、攪拌する。 B.成分(2)、(7)及び(8)を混合する。 C.BをAに加え、混合した後、冷却してパックを得
た。
(Production method) A. Mixing the components (1), (3) to (6) and (9),
Heat to 70 ° C. and stir. B. Mix components (2), (7) and (8). C. B was added to A, mixed, and cooled to obtain a pack.

【0056】実施例6のパックは、経時安定性に優れ、
皮膚に適用することによって、肌のはり、つやが改善さ
れ、肌のくすみや皮膚の老化を防止するものであった。
The pack of Example 6 has excellent stability over time,
By applying to the skin, the abrasion and luster of the skin were improved, and dullness of the skin and aging of the skin were prevented.

【0057】実施例7 リップクリーム:次に示す処方
及び下記製法でリップクリームを調製した。 (処方) (%) (1)マイクロクリスタリンワックス 9.0 (2)固形パラフィン 8.0 (3)ワセリン 15.0 (4)エチルヘキサン酸セチル 15.0 (5)流動パラフィン 8.0 (6)ヒマシ油 残量 (7)高純度リグナン配糖体精製物*1 0.02 (8)β−カロチン*2 0.01 (9)マンニトール*3 0.002 (10)香料 適量 *1 参考例3で製造したもの *2 和光純薬社製 *3 関東化学社製
Example 7 Lip cream: A lip cream was prepared according to the following formulation and the following method. (Prescription) (%) (1) Microcrystalline wax 9.0 (2) Solid paraffin 8.0 (3) Vaseline 15.0 (4) Cetyl ethylhexanoate 15.0 (5) Liquid paraffin 8.0 (6) ) Castor oil Remaining amount (7) Purified lignan glycoside high-purity * 1 0.02 (8) β-carotene * 2 0.01 (9) Mannitol * 3 0.002 (10) Perfume appropriate amount * 1 Reference example * 2 Wako Pure Chemical Co., Ltd. * 3 Kanto Chemical Co., Ltd.

【0058】(製法) A.成分(1)〜(6)を100〜110℃にて加熱溶
解する。 B.Aに成分(7)〜(10)を90℃にて撹拌混合す
る。 C.Bを冷却・成型してリップクリームを得た。
(Production method) The components (1) to (6) are heated and dissolved at 100 to 110 ° C. B. A is mixed with the components (7) to (10) at 90 ° C. C. B was cooled and molded to obtain a lip balm.

【0059】実施例7のリップクリームは、経時安定
性、使用感及び仕上がりに優れ、唇に適用することによ
り、唇を滑らかに保ち、荒れを防止するものであった。
The lip balm of Example 7 was excellent in stability over time, feeling in use and finish, and when applied to the lips, kept the lips smooth and prevented roughening.

【0060】実施例8 パウダーファンデーション:次
に示す処方及び下記製法でパウダーファンデーションを
調製した。 (処方) (%) (1)マイカ 50.0 (2)酸化チタン 15.0 (3)ナイロンパウダー 5.0 (4)カオリン 残量 (5)着色顔料 3.0 (6)パラメトキシケイ皮酸2−エチルヘキシル 2.0 (7)ジメチルポリシロキサン 2.0 (8)スクワラン 3.0 (9)トリオクタン酸グリセリル 2.0 (10)ワセリン 1.0 (11)粗リグナン配糖体*1 0.02 (12)トリプトファン*2 0.02 (13)香料 適量 *1 参考例2で製造したもの *2 関東化学社製
Example 8 Powder foundation: A powder foundation was prepared according to the following formulation and the following production method. (Prescription) (%) (1) Mica 50.0 (2) Titanium oxide 15.0 (3) Nylon powder 5.0 (4) Remaining kaolin (5) Color pigment 3.0 (6) Paramethoxycinnamon 2-ethylhexyl acid 2.0 (7) dimethyl polysiloxane 2.0 (8) squalane 3.0 (9) glyceryl trioctanoate 2.0 (10) petrolatum 1.0 (11) crude lignan glycoside * 10 .02 (12) tryptophan * 2 0.02 (13) perfume appropriate amount * 1 manufactured in Reference Example 2 * 2 manufactured by Kanto Chemical Co.

【0061】(製法) A.成分(1)〜(5)を混合する。 B.成分(6)〜(13)を加熱溶解したものを添加混
合して粉砕する。 C.Bを金皿に充填しプレス成形して、パウダーファン
デーションを得た。
(Production Method) Mix components (1) to (5). B. Components obtained by heating and dissolving the components (6) to (13) are added, mixed and pulverized. C. B was filled in a metal plate and press-molded to obtain a powder foundation.

【0062】実施例8のパウダーファンデーションは、
経時安定性、使用感及び仕上がりに優れ、皮膚に適用す
ることにより、肌のくすみ、荒れ等を抑え、皮膚の老化
を防止するものであった。
The powder foundation of Example 8 is
It was excellent in stability over time, feeling in use, and finish, and was applied to skin to suppress dullness and roughness of the skin and prevent skin aging.

【0063】[0063]

【発明の効果】以上記述したように、リグナン配糖体と
活性酸素除去剤とを組み合わせることにより、活性酸素
除去剤の本来有する効能を十分に発揮させることができ
る。すなわち、皮膚中での活性酸素生成に起因する過酸
化脂質の生成、炎症、黒化、老化等に対し極めて高い改
善及び予防効果を有するため、美容や医療において極め
て有用なものである。
As described above, by combining the lignan glycoside with the active oxygen scavenger, the original effects of the active oxygen scavenger can be fully exhibited. That is, it has extremely high improvement and prevention effects on lipid peroxide generation, inflammation, blackening, aging, etc. due to active oxygen generation in the skin, and is therefore extremely useful in beauty and medicine.

フロントページの続き (51)Int.Cl.6 識別記号 FI A61K 7/00 AGZ A61K 7/00 AGZK 7/40 7/40 31/70 ADA 31/70 ADA (72)発明者 妹尾 正巳 東京都北区田端新町3−26−2−1004 (72)発明者 亀山 久美 東京都豊島区上池袋4−11−9−512Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 7/00 AGZ A61K 7/00 AGZK 7/40 7/40 31/70 ADA 31/70 ADA (72) Inventor Masami Senoo Kita-ku, Tokyo 3-26-2-1004 Tabata Shinmachi (72) Inventor Kumi Kameyama 4-11-9-512 Kamiikebukuro, Toshima-ku, Tokyo

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】 次の成分(A)及び(B) (A)リグナン配糖体 (B)活性酸素除去剤を含有することを特徴とする組成
物。
1. A composition comprising the following components (A) and (B): (A) a lignan glycoside (B) an active oxygen scavenger.
【請求項2】 リグナン配糖体が、下記の構造式(I)
で示されるセサミノール配糖体である請求項1記載の組
成物。 【化1】
2. A lignan glycoside having the following structural formula (I):
The composition according to claim 1, which is a sesaminol glycoside represented by the formula: Embedded image
【請求項3】 リグナン配糖体が、下記の構造式(II
−a)、(II−b)もしくは(II−c)で示される
セサミノール配糖体の1種または2種以上を主成分とす
るリグナン配糖体である請求項1または2記載の組成
物。 【化2】 【化3】 【化4】
3. A lignan glycoside having the following structural formula (II)
The composition according to claim 1 or 2, which is a lignan glycoside containing one or more of sesaminol glycosides represented by -a), (II-b) or (II-c) as a main component. . Embedded image Embedded image Embedded image
【請求項4】 リグナン配糖体がゴマ種子やその加湿物
もしくは発芽体、またはそれらの粉砕物、またはそれら
の脱脂物の含水低級アルコール抽出物である請求項1、
2または3記載の組成物。
4. The lignan glycoside is a hydrated lower alcohol extract of sesame seeds, humidified or germinated bodies thereof, crushed products thereof, or defatted products thereof.
4. The composition according to 2 or 3.
【請求項5】 活性酸素除去剤が、スーパーオキシドデ
ィスムターゼ(SOD)、カタラーゼ、グルタチオンペ
ルオキシダーゼ等の酵素類、マンニトール、ベーターカ
ロチン等のカロテノイド類、ハイドロキノン、ビリルビ
ン、トリプトファン、ヒスチジン、クエルセチン、クエ
ルシトリン、カテキン及びその誘導体、没食子酸及びそ
の誘導体、オウゴン抽出物及びイチョウ抽出物等のフラ
ボノイドを成分中に含む植物抽出物、ユキノシタ抽出
物、ゴカヒ抽出物、ヤシャジツ抽出物及びジコッピ抽出
物から選ばれる1種または2種以上である請求項1、
2、3または4記載の組成物。
5. An active oxygen scavenger comprising enzymes such as superoxide dismutase (SOD), catalase and glutathione peroxidase; carotenoids such as mannitol and beta-carotene; hydroquinone, bilirubin, tryptophan, histidine, quercetin, quercitrin, and catechin And a derivative thereof, a gallic acid and a derivative thereof, a plant extract containing flavonoids such as a gougon extract and a ginkgo extract in a component, a saxifraga extract, a gokahi extract, a yasazitsu extract and a dickopi extract, or Claim 1 which is two or more kinds.
The composition according to 2, 3 or 4.
JP9099761A 1997-04-01 1997-04-01 Composition Pending JPH10279461A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9099761A JPH10279461A (en) 1997-04-01 1997-04-01 Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9099761A JPH10279461A (en) 1997-04-01 1997-04-01 Composition

Publications (1)

Publication Number Publication Date
JPH10279461A true JPH10279461A (en) 1998-10-20

Family

ID=14255970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9099761A Pending JPH10279461A (en) 1997-04-01 1997-04-01 Composition

Country Status (1)

Country Link
JP (1) JPH10279461A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002193731A (en) * 2000-12-27 2002-07-10 Kanebo Ltd Cosmetic
WO2002080702A1 (en) * 2001-04-04 2002-10-17 Unilever N.V. Use of lignans in foods
US7582677B2 (en) 2002-06-19 2009-09-01 Hormos Medical Corp. Lignan formulations

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0532556A (en) * 1991-07-30 1993-02-09 Kose Corp Skin agent for external use
JPH0665043A (en) * 1992-08-17 1994-03-08 Kose Corp Skin external preparation
JPH06128141A (en) * 1992-10-16 1994-05-10 Kose Corp External agent for skin
JPH06336419A (en) * 1993-05-28 1994-12-06 Kose Corp External agent for skin
JPH07277939A (en) * 1994-04-05 1995-10-24 Dowa Mining Co Ltd Skin external preparation
JPH0899820A (en) * 1994-09-30 1996-04-16 Kose Corp Skin external agent
JPH08208685A (en) * 1995-02-06 1996-08-13 Nisshin Oil Mills Ltd:The Hydroxy free radical eliminating activator

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0532556A (en) * 1991-07-30 1993-02-09 Kose Corp Skin agent for external use
JPH0665043A (en) * 1992-08-17 1994-03-08 Kose Corp Skin external preparation
JPH06128141A (en) * 1992-10-16 1994-05-10 Kose Corp External agent for skin
JPH06336419A (en) * 1993-05-28 1994-12-06 Kose Corp External agent for skin
JPH07277939A (en) * 1994-04-05 1995-10-24 Dowa Mining Co Ltd Skin external preparation
JPH0899820A (en) * 1994-09-30 1996-04-16 Kose Corp Skin external agent
JPH08208685A (en) * 1995-02-06 1996-08-13 Nisshin Oil Mills Ltd:The Hydroxy free radical eliminating activator

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002193731A (en) * 2000-12-27 2002-07-10 Kanebo Ltd Cosmetic
WO2002080702A1 (en) * 2001-04-04 2002-10-17 Unilever N.V. Use of lignans in foods
US7582677B2 (en) 2002-06-19 2009-09-01 Hormos Medical Corp. Lignan formulations

Similar Documents

Publication Publication Date Title
US8263565B2 (en) Nanoemulsion comprising metabolites of ginseng saponin as an active component and a method for preparing the same, and a skin-care composition for anti-aging containing the same
JPH0899820A (en) Skin external agent
JPH0665044A (en) Skin external preparation
JP2000212026A (en) Preparation for external use for skin
JP2000327550A (en) Skin preparation for external use
KR100465976B1 (en) Nanoemulsion having Ginsenoside F1 by nano-emulsion technology, and skin care and pharmaceutical compositions for external applications utilizing thereof
KR20030094523A (en) Microemulsion comprising metabolites of ginseng saponin as effective component and preparation method, and skin care compositions for antiaging agent utilizing thereof
KR0154366B1 (en) Liquid crystal gel for stabilized oil soluble extracts of glyoyrrhizae radix and cosmetic compositions containing the same
JPH10279461A (en) Composition
JPH06128142A (en) External agent for skin
JP2001163755A (en) Preparation for external use for skin
JPH10279458A (en) Composition
EP4106720B1 (en) Topically administrable lysate of dedifferentiated cells of the plant helichrysum stoechas for moisturizing skin
JPH10279464A (en) Skin preparation for external use
JPH10279462A (en) Skin preparation for external use
JP2000026228A (en) Collagenase inhibitor, moisturizer, and cosmetic or food containing the same
JPH10279460A (en) Skin preparation for external use
JP2824412B2 (en) Cosmetics
JP2006213649A (en) Cell activator, collagen production accelerator and antioxidant composed of soybean saponin and cosmetic raw material comprising the same cell activator, the same collagen production accelerator and/or the same antioxidant and cosmetic composition comprising the same cosmetic raw material
JPH10279468A (en) Skin preparation for external use
JP3101090B2 (en) External preparation for skin
KR101945402B1 (en) Emulsion Containing Sea Buckthorn Oil And Cosmetic Composition For Moisturizing Skin Comprising The Same
JPH10279441A (en) Hair cosmetic
KR100465977B1 (en) Nanoemulsion having Compound K by nano-emulsion technology, and skin care and pharmaceutical compositions for external applications utilizing thereof
JP2001270818A (en) Skin cosmetic

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040401

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20040401

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040528

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20040701

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20050126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050712